The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802)—Sub-group analysis by KRAS Exon2 status.
 
Michio Nakamura
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Satoshi Yuki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
 
Kentaro Sawada
No Relationships to Disclose
 
Ayane Oba
No Relationships to Disclose
 
Atsushi Sato
No Relationships to Disclose
 
Takashi Kato
No Relationships to Disclose
 
Takashi Meguro
No Relationships to Disclose
 
Nobuyuki Ehira
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Kazunori Eto
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Masakazu Abe
No Relationships to Disclose
 
Kanji Kato
No Relationships to Disclose
 
Mineo Kudo
No Relationships to Disclose
 
Kencho Miyashita
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)